RGEN vs. EXEL, HALO, NBIX, ADPT, BIIB, QGEN, PCVX, RVMD, TECH, and KRYS
Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Exelixis (EXEL), Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Bio-Techne (TECH), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
Exelixis (NASDAQ:EXEL) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.
Exelixis has a net margin of 11.10% compared to Exelixis' net margin of 2.44%. Repligen's return on equity of 8.85% beat Exelixis' return on equity.
Exelixis has higher revenue and earnings than Repligen. Exelixis is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
85.3% of Exelixis shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 2.9% of Exelixis shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Repligen had 8 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Repligen and 13 mentions for Exelixis. Repligen's average media sentiment score of 0.80 beat Exelixis' score of 0.73 indicating that Exelixis is being referred to more favorably in the media.
Exelixis received 176 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 68.12% of users gave Exelixis an outperform vote while only 68.08% of users gave Repligen an outperform vote.
Exelixis currently has a consensus target price of $26.13, suggesting a potential upside of 27.69%. Repligen has a consensus target price of $197.75, suggesting a potential upside of 27.85%. Given Exelixis' stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Exelixis.
Exelixis has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Summary
Exelixis beats Repligen on 11 of the 18 factors compared between the two stocks.
Get Repligen News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repligen Competitors List
Related Companies and Tools
